THE ROLE OF OSTEOPROTEGERIN SYSTEM /RANKL/RANK IN PATHOGENESIS OF AORTIC STENOSIS

Aim. To assess the concentrations of osteoprotegerin (OPG) and soluble ligand of the receptor of transcription activator factor kappa-B (sRANKL) in the blood serum of patients with various grade of aortic stenosis (AS) severity.

Material and methods. Totally, 247 AS patients studied of various grade: 46 — mild, 53 — moderate and 149 — severe. Of those 132 (53%) with bicuspid aortic valve (BAV) and 115 (47%) with tricuspid (TAV). Controls were 58 patients with no valvular pathology or coronary heart disease. All patients underwent lipid profile measurement, serum C-reactive protein (CRP) and OPG, sRANKL.

Results. In all studied groups of AS patients there was increased level of sRANKL in blood serum, comparing to controls (BAV =0,37 [0,32;0,53] pM/L, TAV =0,38 [0,33;0,50] pM/L, controls 0,30 [0,21;0,39] pM/L; р<0,0001). Concentration of OPG was increased only in TAV: 6,99 [5,19;9,90] pM/L; comparing to 5,23 [4,30;7,09] pM/L in BAV (р=0,0008). A hypothesis proposed that OPG concentration increase is compensatory and takes place as a response to the increase of the concentration or due to loss of sensitivity to sRANKL.

Conclusion. Development of AS is related to disorders in OPG/RANKL system, and these revealed changes might have significant diagnostic and predictive value, especially in TAV.

aortic stenosis, calcinosis, biomarkers, osteoprotegerin, sRANKL

1. Schweighofer N, Aigelsreiter A, Trummer O, et al. Direct comparison of regulators of calcification between bone and vessels in humans. Bone 2016; 88: 31-8. DOI: 10.1016/j.bone.2016.04.016.

2. Pasipoularides A. Calcific aortic valve disease: part 1 — molecular pathogenetic aspects, hemodynamics, and adaptive feedbacks. J Cardiovasc Transl Res 2016; 9 (2): 102-18. DOI: 10.1007/s12265-016-9679-z.

3. Lis GJ, Czubek U, Jasek-Gajda E, et al. Influence of osteoclasts and osteoprotegerin on the mode of calcific degeneration of aortic valves. Pol Arch Med Wewn 2016; 126 (3): 14958. DOI: 10.20452/pamw.3326.

4. Fojt R, Pirk J, Kamenicky P, et al. Values of osteoprotegerin in aortic valve tissue in patients with significant aortic stenosis depend on the existence of concomitant coronary artery disease. Cardiovasc Pathol 2016; 25 (3):181-4. DOI: 10.1016/j.carpath.2015.12.003.

5. Irtyuga O, Malashicheva A, Zhiduleva E, et al. NOTCH1 mutations in aortic stenosis association with osteoprotegerin/RANK/RANKL. BioMed Res Int 2017; 2017:6917907. DOI: 10.1155/2017/6917907.

6. Irtiuga OB, Zhiduleva EV, Dubrovskaia OB, et al. Concentration of osteoprotegerin and RANKL in blood serum of patients with aortic stenosis. Kardiologyia 2014; 54 (6): 44-8. (In Russ.) Иртюга О. Б., Жидулева Е. В., Дубровская О. Б. и др. Концентрация остеопротегерина и растворимого лиганда рецептора активатора фактора транскрипции каппа В в сыворотке крови у пациентов с аортальным стенозом. Кардиология 2014; 54 (6): 44-8. DOI: 10.18565/cardio.2014.6.44-8.

7. Irtyuga OB, Zhiduleva EV, Murtazalieva PM, et al. Pathogenetic mechanisms of calcification of the aortic valve: analysis of own data. Translational Medicine 2016; 3 (1): 21-8. (In Russ.) Иртюга О. Б., Жидулева Е. В., Муртазалиева П. М. и др. Патогенетические механизмы кальцификации аортального клапана: анализ собственных данных. Трансляционная медицина 2016; 3 (1): 22-8. DOI: 10.18705/2311-4495-2016-3-1-21-28.

8. Baumgartner H, Hung J, Bermejo J, et al. Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice. J Am Soc Echocardiogr 2009; 22: 1-23. DOI: 10.1016/j.echo.2008.11.029.

9. Lindman BR, Clavel MA, Mathieu P, et al. Calcific aortic stenosis. Nat Rev Dis Primers 2016; 2: 16006. DOI: 10.1038/nrdp.2016.6.

10. Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J 2017; 38 (36): 2739-91. DOI: 10.1093/eurheartj/ehx391

11. Akat K, Kaden JJ, Schmitz F, et al. Calcium metabolism in adults with severe aortic valve stenosis and preserved renal function. Am J Cardiol 2010; 105 (6): 862-4. DOI: 10.1016/j.amjcard.2009.10.065.

12. Gamal RM, Gamal WM, Ghandour AM, et al. Study of the osteoprotegerin/ receptor activator of nuclear factor-kB ligand system association with inflammation and atherosclerosis in systemic sclerosis. Immunol Invest 2018 Jan 16: 1-10. DOI: 10.1080/08820139.2017.1423499.

13. Siasos G, Oikonomou E, Maniatis K, et al. Prognostic significance of arterial stiffness and osteoprotegerin in patients with stable coronary artery disease. Eur J Clin Invest 2018; e12890. DOI: 10.1111/eci.12890.

14. Blazquez-Medela AM, Garcia-Ortiz L, Gomez-Marcos MA, et al. Osteoprotegerin is associated with cardiovascular risk in hypertension and/or diabetes. Eur J Clin Invest 2012; 42 (5): 548-56. DOI: 10.1111/j.1365-2362.2011.02619.x.

15. Uzui H, Morishita T, Nakano A, et al. Effects of combination therapy with olmesartan and azelnidipine on serum osteoprotegerin in patients with hypertension. J Cardiovasc Pharmacol Ther 2014; 19 (3): 304-9. DOI: 10.1177/1074248413511692.